Resolian
Founded in 2008 as Alliance Pharma, Resolian began as a bioanalytical contract research organization headquartered in Malvern, Pennsylvania.
The company built a strong regional reputation for its analytical rigor and responsive customer service, primarily supporting pharmaceutical and biotech clients in the United States. In 2021, Ampersand Capital Partners acquired a majority stake in the business, marking the start of a global growth strategy.
Resolian is now a leading global bioanalytical laboratory with facilities in the U.S., U.K., Australia, and China, enabling preclinical and clinical trial sponsors to seamlessly conduct small or large molecule studies across multiple continents with a single, harmonized partner. Built through a series of targeted acquisitions and greenfield investments, Resolian is uniquely positioned to serve the growing global demand for advanced scientific, high-quality, flexible, and time-sensitive bioanalytical services.
Keys to Success
Ampersand’s 2021 investment came at a pivotal moment for Alliance Pharma, an already well-respected bioanalytical CRO. The company’s founder wished to transition from day-to-day operations, opening the door to a global build-out and long-term growth. Ampersand helped chart a path toward geographic expansion, global multi-site integration, and enhanced scientific depth. The strategy quickly gained pace. In 2022, Resolian (then Alliance) acquired Drug Development Solutions (DDS), a similarly sized U.K.-based bioanalytical division of LGC. The acquisition immediately expanded Resolian’s European footprint and brought in KKR as a co-investor to support future growth.
In Australia, early-phase clinical trials were booming, driven by fast regulatory approval timelines and R&D tax incentives. To capitalize on this expanding market, Resolian partnered with an experienced local management team, some of whom had previously worked at Alliance Pharma, to build and launch a new Brisbane-based laboratory. The site became fully operational in early 2023, quickly becoming a strategic bridge to the broader and fast-growing Asia-Pacific sponsor markets. An acquisition of a China-based bioanalytical lab would follow several months later, further strengthening the company’s Asia-Pacific footprint and capabilities in bioanalytical and biomarker analyses to better support customers globally.
In 2023, the company was rebranded “Resolian”, leveraging the company’s commitment to being “Resolute”, “Resolving” any client matters, and having the highest “Resolution” with analytical techniques.
From the outset, Ampersand and Resolian shared a vision: build a differentiated global platform that could compete with much larger CROs while retaining the responsiveness and client-first culture of a specialty provider.
The team next set its sights on China, an increasingly important country for global trial sponsors. In November 2023, Resolian acquired Denali Medpharma, a lab founded by U.S.-trained scientists operating to Western standards. A strong cultural and scientific alignment made Denali a natural addition to the Resolian network.
“Resolian’s expansion wasn’t just about adding locations — it was about strategically elevating its global scientific capabilities and customer support. Each acquisition and new site brought unique expertise, and by continuing to harmonize our processes across continents, we’re delivering consistent, high-quality bioanalytical, biomarker, and analytical material science services to our clients as their projects move across the development continuum. Ampersand’s support has helped position Resolian to meet clients’ needs on a global scale.” –Rob Stachlewitz, CEO, Resolian
Today, Resolian is one of the only specialty bioanalytical service providers with small and large molecule lab operations in virtually every key clinical trial market. Its clients — from emerging biotech to global pharma — benefit from consistent methods, harmonized processes, and the ability to seamlessly transfer assays across continents.
By expanding its scientific capabilities and scaling its geographic reach without sacrificing service quality, Resolian has positioned itself as a true partner to global drug developers. With continued backing from Ampersand, the company is poised to grow its leadership role in the bioanalytical space and help resolve complex challenges wherever trials are run.
“Our expansion into the U.K., China, and Australia was a strategic and well-supported initiative. Through Ampersand’s partnership, Resolian established a strong foundation to operate globally while maintaining excellence in local delivery.” –Frank Li, Founder
Disclosure: The case study and results included are for illustration purposes only and may not be typical. The case study should not be considered specific investment advice, do not take into consideration a specific situation, and are not intended to make an offer or solicitation for the sale or purchase of any securities or investment strategies. Investments involve risk and are not guaranteed. Case study testimonials were provided by clients between May 2024 – July 2024. The client was not compensated, nor are their material conflicts of interest that would affect the given testimony. The testimony may not be representative of the experience of other current clients and does not provide a guarantee of future performance success or similar services.
The statements provided herein are made by certain founders or executives of Ampersand’s past and/or current portfolio companies. Certain statements made herein are considered “testimonials” and express approval, support, or a recommendation of Ampersand, or describe the individual’s experience with Ampersand. The individual has not been directly compensated for making these statements. However, a portfolio company in which the individual held a significant equity interest may have received financial investment from Ampersand through one or more funds managed by Ampersand. As such, the individual may have an indirect financial interest in the success of Ampersand’s activities or in presenting Ampersand in a favorable light. Additionally, the individual may be an Operating Partner or Executive Advisor with Ampersand. As an Operating Partner or Executive Advisor, the individual performs certain services for Ampersand and may be compensated for providing these services. These potential conflicts of interest should be considered by prospective investors when evaluating the individual’s testimonial.
The individual’s statements reflect past, subjective experiences and are not indicative of future performance or success. Any testimonial made by the individual does not guarantee that future clients or portfolio companies will have similar experiences or achieve similar outcomes. Investment outcomes are subject to numerous risks and uncertainties, and there can be no assurance that any investment will achieve its objectives or that investors will not experience losses. This case study should not be considered specific investment advice, does not take into account any specific situation, and is not intended to make an offer or solicitation for the sale or purchase of any securities or investment strategies. Investments involve risk and are not guaranteed.